ArticleThe oncologist2024

First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.

Sarina A Piha-Paul et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.